MP02-15 PSA-CHANGES AND MICTURITION IMPROVEMENT 5-YEARS AFTER THULIUM VAPOENUCLEATION OF THE PROSTATE FOR SYMPTOMATIC BENIGN PROSTATIC OBSTRUCTION

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I1 Apr 2017MP02-15 PSA-CHANGES AND MICTURITION IMPROVEMENT 5-YEARS AFTER THULIUM VAPOENUCLEATION OF THE PROSTATE FOR SYMPTOMATIC BENIGN PROSTATIC OBSTRUCTION Christopher Netsch, Benedikt Becker, Ann Kathrin Orywal, Thomas Herrmann, and Andreas Gross Christopher NetschChristopher Netsch More articles by this author , Benedikt BeckerBenedikt Becker More articles by this author , Ann Kathrin OrywalAnn Kathrin Orywal More articles by this author , Thomas HerrmannThomas Herrmann More articles by this author , and Andreas GrossAndreas Gross More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.111AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To assess the long-term results of thulium vapoenucleation of the prostate (ThuVEP) for the treatment of symptomatic benign prostatic obstruction (BPO) retrospectively. METHODS 500 patients with symptomatic BPO were treated with ThuVEP and consecutive mechanical morcellation between January 2007 and January 2010 at our institution. Patients were reassessed 1 and 5 years after ThuVEP with International Prostate Symptom Score (IPSS), Quality of Life (QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR), PSA, and prostate volume measured by transrectal ultrasound. To assess treatment effects, patients were divided into two groups according to the prostate volume: group A (<60ml) and group B (>60ml). Patient data is presented as median (interquartile range). RESULTS 131 patients completed the 5-year follow-up and were included in the final analysis. IPSS, QoL, Qmax, and PVR improved significantly and continued to do so during 5-year follow-up (p≤0.001). At 1-year follow-up, the median prostate volume (50 ml vs. 13 ml, p<0.001) decreased significantly with a median prostate volume reduction of 80.8% (64.3-88%). Median PSA was significantly reduced at 1-year (0.83 μl/l) and 5-year (0.72 μg/l) follow-up as compared to median preoperative PSA (3.39 μg/l) (p≤0.001). The median PSA-reduction was 77.1% (51.5-89.3%) at 5-year follow-up and significantly different between group A (70.2% (42.7-87.3)%) and group B (83.5% (70.2-91.5%)) (p≤0.006). IPSS was significantly lower at 5-year follow-up in group B compared to group A (2.5 vs. 6, p<0.001), while Qmax, QoL, PVR showed no differences at 5-year follow-up between the groups. Bladder-neck contractures (n=4) and urethral strictures (n=4) developed 3.1% of the patients each. Three patients (2.3%) were re-treated during follow-up for recurrent prostatic tissue. CONCLUSIONS ThuVEP is a durable procedure for the treatment of symptomatic BPO with regard to micturition improvement and prostate volume reduction. The reintervention rate of the ThuVEP procedure at long-term follow-up was low. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e16 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Christopher Netsch More articles by this author Benedikt Becker More articles by this author Ann Kathrin Orywal More articles by this author Thomas Herrmann More articles by this author Andreas Gross More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...